Opna Bio’s OPN-6602 Gains Orphan Drug Status for Multiple Myeloma
Opna Bio Secures Orphan Drug Designation for OPN-6602 in Multiple Myeloma Opna Bio, a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics, has announced that…
AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors
AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has…
Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma
Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma Tivic Health Systems, Inc. (Nasdaq: TIVC) has taken a major step toward expanding its therapeutic portfolio by…
Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium
Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium Ferring Pharmaceuticals recently announced that three abstracts showcasing ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025…
Alto Neuroscience Reports Positive Interim Results from ALTO-300 Phase 2b MDD Trial
Alto Neuroscience Reports Positive Interim Analysis Outcome for ALTO-300 Phase 2b Trial in Major Depressive Disorder Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on developing precision…
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely…
Seaport Therapeutics Publishes Research on Glyph™ Platform’s 55% Lymphatic Drug Absorption
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in…
Taiho Oncology Europe Announces Availability of Futibatinib in Italy for the Treatment of Cholangiocarcinoma
Taiho Oncology Europe Announces Availability of Futibatinib in Italy for the Treatment of Cholangiocarcinoma Taiho Oncology Europe, a subsidiary of Taiho Pharmaceutical Co., Ltd., has officially announced the availability of…
GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study
GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing…
Arrowhead Pharmaceuticals Completes Global License and Collaboration Deal with Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has successfully closed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT), which was initially announced on November 26, 2024. The closing of…
Incyte Announces Q4 and Full-Year 2024 Financial Results, Shares 2025 Guidance and R&D Milestones
Incyte Announces Q4 and Full-Year 2024 Financial Results, Shares 2025 Guidance and R&D Milestones Incyte reported its financial results for the fourth quarter and full year ended December 31, 2024.…
Aurion Biotech Names Donald Munoz as Chief Financial Officer
Aurion Biotech, Inc. (Aurion), a company dedicated to restoring vision for millions through transformative regenerative therapies, has announced the appointment of Donald Munoz as Chief Financial Officer (CFO). Munoz will…